LeMaitre Vascular Inc (LMAT)vsMedline Inc. Class A Common Stock (MDLN)
LMAT
LeMaitre Vascular Inc
$80.59
+2.27%
HEALTHCARE · Cap: $1.82B
MDLN
Medline Inc. Class A Common Stock
$32.53
+0.43%
HEALTHCARE · Cap: $43.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 11308% more annual revenue ($29.94B vs $262.43M). LMAT leads profitability with a 25.0% profit margin vs 2.3%. LMAT trades at a lower P/E of 27.8x. LMAT earns a higher WallStSmart Score of 62/100 (C+).
LMAT
Buy62
out of 100
Grade: C+
MDLN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.5%
Fair Value
$56.44
Current Price
$80.59
$24.15 premium
Intrinsic value data unavailable for MDLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.0%
Earnings expanding 22.6% YoY
Earnings expanding 262.0% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
2.3% margin — thin
Operating margin of 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : LMAT
The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 25.0% and operating margin at 29.0%.
Bull Case : MDLN
The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.
Bear Case : LMAT
The primary concerns for LMAT are PEG Ratio, P/E Ratio, Market Cap.
Bear Case : MDLN
The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.6x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
LMAT profiles as a mature stock while MDLN is a value play — different risk/reward profiles.
MDLN is growing revenue faster at 11.6% — sustainability is the question.
MDLN generates stronger free cash flow (604M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LMAT scores higher overall (62/100 vs 52/100), backed by strong 25.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LeMaitre Vascular Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?